Adderall and Adderall XR amphetamine neurology data

The study is the first of 3 studies sponsored by FDA and the U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ). The studies are part of a safety review initiated in 2007 evaluating ADHD drugs and the potential for increased risk of heart attack, stroke or other cardiovascular problems (see BioCentury, Oct. 1, 2007). Based on the results, FDA updated a safety review and continues to recommend that healthcare professionals prescribe ADHD medications according to the professional prescribing label. FDA said it is reviewing the results from the second and third studies, which are analyzing ADHD users aged 25-64 years. ...